The First Daily Cholesterol Pill That Beats Statins and Skips the Needle Just Got Approved

For people whose LDL will not budge on statins, the only add-on options have been injections — until July 2026. The FDA approved enlicitide (Lipfendra), the first pill that blocks PCSK9, the protein that lets the liver recycle cholesterol. It is a once-daily tablet that cut LDL by more than half in trials.

Key Takeaways

• The FDA approved enlicitide (Lipfendra) on July 16–17, 2026 as the first oral PCSK9 inhibitor, taken as a 20 mg daily tablet (FDA, 2026).
• In two phase 3 CORALreef trials it lowered LDL cholesterol by about 56% and 59% versus placebo, matching the efficacy of injectable PCSK9 drugs (FDA; NEJM, 2026).
• It is intended as an add-on to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, often alongside a statin (FDA, 2026).
• Because it is a pill, clinicians expect wider use than injectable PCSK9 drugs, which many patients avoided (ACC, 2026).

What Makes Enlicitide Different From a Statin?

Statins slow cholesterol production in the liver; PCSK9 inhibitors stop the liver from destroying its LDL receptors, so more LDL gets cleared from blood. Until now every PCSK9 drug was an injection (evolocumab, alirocumab, inclisiran). Enlicitide is a macrocyclic peptide taken by mouth, the first of its kind, which removes the needle that kept many patients away (FDA, 2026). It is not a statin replacement — it is usually added on top of a maximally tolerated statin when LDL is still too high.

Citation capsule: Enlicitide is the first oral PCSK9 inhibitor, a 20 mg daily tablet that works downstream of statins by preserving LDL receptors, offering an injection-free add-on for patients who need further LDL lowering (FDA, 2026).

This is the practical counterpart to our Lp(a) test article — once you know your risk, pills like this are the tool.

How Well Does It Lower LDL?

In the two CORALreef phase 3 trials, enlicitide reduced LDL cholesterol by roughly 56% and 59% compared with placebo, performance on par with the injectable PCSK9 agents (FDA; NEJM, 2026). The trials enrolled more than 3,200 patients with hypercholesterolemia on background statin therapy, including a study in heterozygous familial hypercholesterolemia (FDA, 2026). For context, that magnitude of reduction is far beyond what most statins alone achieve at standard doses.

Citation capsule: Across the CORALreef program enlicitide lowered LDL cholesterol by about 56–59% versus placebo in over 3,200 statin-treated adults, matching injectable PCSK9 inhibitors and qualifying it as a potent add-on (NEJM; FDA, 2026).

If muscle side effects limited your statin, our statin muscle aches and switching guide explains the alternatives ladder.

Who Should Consider the New Pill?

The approved group is adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise — most often people already on a statin whose LDL is still above goal (FDA, 2026). Familial hypercholesterolemia is a strong candidate, since these patients often need multiple drugs to reach target. Our cholesterol screening starts at 19 article explains who should be screened early.

Citation capsule: Enlicitide is approved for adults with hypercholesterolemia — including familial hypercholesterolemia — as an add-on to statins and lifestyle, targeting the many patients who cannot reach LDL goals on a statin alone (FDA, 2026).

The 2026 dyslipidemia guideline lowered LDL targets, which means more people will need an add-on like this.

What Are the Caveats?

It is new, so long-term real-world data are thin, and cost and access are unsettled in 2026 (ACC, 2026). It is not for everyone — people who tolerate statins well and hit goal generally do not need it. And it does not replace lifestyle: diet, exercise, and not smoking remain the base layer. Clinicians also stress it may widen equitable access precisely because a daily pill is easier to prescribe and adhere to than a biweekly injection (ACC, 2026).

Citation capsule: As a 2026 approval, enlicitide lacks long-term real-world data and its pricing is uncertain, but its oral form may improve access and adherence versus injectable PCSK9 drugs for patients who need extra LDL lowering (ACC, 2026).

Frequently Asked Questions

Is enlicitide a replacement for my statin?

Usually no — it is added to a statin and lifestyle when LDL stays above goal (FDA, 2026).

How much does it lower cholesterol?

About 56–59% versus placebo in trials, similar to injectable PCSK9 drugs (NEJM; FDA, 2026).

Do I still need the Lp(a) or ApoB test?

Yes. Enlicitide addresses LDL; knowing Lp(a) and ApoB still reframes your overall risk (AHA/ACC, 2026).

When will it be available?

The FDA approved it in July 2026; availability and coverage were rolling out through the second half of the year (FDA, 2026).

Conclusion

Enlicitide is the first cholesterol pill that works like the injectable PCSK9 drugs, cutting LDL by more than half without a needle. For the many patients whose numbers will not move on statins alone — especially those with familial hypercholesterolemia — it is a meaningful new option. It joins diet, exercise, and statins as another rung on the ladder to goal, not a reason to skip them.

Sources

• U.S. FDA. FDA approves first oral PCSK9 inhibitor (enlicitide, Lipfendra) to lower LDL cholesterol. July 16–17, 2026. Retrieved 2026-08-11. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol
• Navar AM, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. N Engl J Med. 2026;394:529-539.
• American College of Cardiology. FDA update: first oral PCSK9 inhibitor approved. July 21, 2026. Retrieved 2026-08-11. https://www.acc.org/latest-in-cardiology/articles/2026/07/21/12/01/fda-update